Alpex Pharma provides production and research and development (R&D) of orally dispersible tablets (ODT) such as fast-melt and effervescent types.
The company has developed a unique proprietary covering orally disintegrating tablet (ODT) technology. High-manufacturing capacity and advanced research and development (R&D) technology makes Alpex Pharma one of the most important companies in the world in the field of fast-melt and effervescent tablets.
Alpex Pharma has state-of-the-art manufacturing and R&D facilities covering 7,000m2.
Alpex Pharma is a drug-delivery company that develops improved pharmaceutical products using proprietary technologies and extensive knowledge, developing and producing pharmaceutical products in the form of effervescent and ODT tablets for various third parties.
Alpex Pharma’s effervescent products are based on a chemical incompatibility between bicarbonate and an acidic source. The reaction is an autocatalytic reaction catalysed by the presence of water and heat, that generates CO2 in solution.
The control of the reaction is made by a strict control of the residual amount of moisture during the process and on the final dosage form (tablets).
Advanced patented technology based on:
wet granulation of drug and excipients in a fluid bed granulator; moisture control during the process and in the manufacturing area; tabletting and packaging.
Alpex Pharma produces pharmaceutical products in a completely dedicated area having also undertaken extensive development activities for third parties. They also identify product opportunities and develop them internally in view of finding interested licensing partners.
The Aplex Pharma development plan includes:
6805 Mezzovico (Lugano)